LONDON/ZURICH (Reuters), May 12 - Glivec (imatinib), which has dramatically improved survival prospects for some cancer patients, can interfere with bone development, according to U.S. researchers.
Results of a study published this week in the New England Journal of Medicine indicated that the drug inhibits bone formation and resorption -- a process known as bone remodeling.
Novartis has not found similar adverse effects in a large database it keeps of clinical trials and postmarketing data, though the study is interesting enough to warrant further research, said a spokesman for the drug maker Novartis AG.
"We have done a review of our safety database.... We're not seeing reporting of these adverse events. But we will be conducting further studies to better understand," he said.
The side effect was detected by Dr. Ellin Berman and colleagues at the Memorial Sloan-Kettering Cancer Center in New York after some patients on the drug developed low levels of serum phosphate, a mineral important in bone formation.
The new finding was based on just 16 patients with low mineral levels, and the full significance of the discovery has yet to be ascertained, the company noted.
Glivec, or Gleevec as it is known in the U.S., was approved five years ago. The drug has transformed life expectancy for people with chronic myelogenous leukaemia (CML) and gastrointestinal stromal tumors (GIST). Five years of use shows patients taking Glivec have a 90% survival rate.
The bone problem is mentioned as an infrequent side effect in prescription information, Novartis said, but the results of the study in which this occurred were not clinically significant.
Last Updated: 2006-05-11 11:57:52 -0400 (Reuters Health)
Related Reading
Androgen deprivation therapy of prostate cancer lowers bone mineral density, May 11, 2006
Copyright © 2006 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
